Retrospective study of nivolumab for patients with recurrent high grade gliomas

Journal of Neuro-oncology
Megan ManticaJan Drappatz

Abstract

Patients with recurrent high-grade gliomas (HGG) have limited treatment options. HGG utilize the PD-1 pathway to evade immune responses. Checkpoint inhibitors have demonstrated safety and clinical activity in patients with recurrent glioblastoma. We explored the efficacy of nivolumab in recurrent HGG with a primary objective of progression free survival (PFS) and overall survival (OS). We retrospectively analyzed HGG patients treated with nivolumab in our institution. We included patients with advanced HGG who received nivolumab at their oncologist's decision. Patients received nivolumab 3 mg/kg every 2 weeks until confirmed progression, intolerable toxicity, death, or physician decision. Radiographic assessments were performed every 8 weeks. Between April 2015 and October 2017, 50 HGG patients received nivolumab. 43 patients received nivolumab with bevacizumab. 44 patients were bevacizumab refractory and 7 patients received nivolumab monotherapy. All had received prior radiation and chemotherapy. 39 adverse events (AEs) were noted [most commonly fatigue (16%) and constipation (10%)]. 4 (8%) patients experienced grade 3-4 AEs. 36 (72%) patients experienced stable disease (SD) at the 2-month assessment. Median duration of SD was...Continue Reading

References

Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie E CombsDaniela Schulz-Ertner
Feb 24, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James J VredenburghHenry S Friedman
Oct 2, 2007·Current Opinion in Oncology·Dieta Brandsma, Martin J van den Bent
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James J VredenburghHenry S Friedman
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jul 14, 2009·Journal of Neuro-oncology·Marc C Chamberlain, Sandra K Johnston
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Oct 20, 2009·Journal of Neuro-oncology·Roy G TorcuatorTom Mikkelsen
May 19, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shannon E FoghMaria Werner-Wasik
Nov 10, 2010·Current Topics in Microbiology and Immunology·Hyun-Tak JinTaku Okazaki
Jun 1, 2011·Journal of Neuro-oncology·Marc C Chamberlain, Sandra K Johnston
Nov 9, 2012·Neuro-oncology·Michael WellerWolfgang Wick
Jul 9, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evanthia GalanisJan C Buckner
Mar 5, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianF Stephen Hodi
Mar 29, 2014·Neuro-oncology·Seunggu J HanNicholas A Butowski
Apr 18, 2014·Journal of Neuro-oncology·Marc C ChamberlainUNKNOWN Brain Tumor Investigational Consortium (BTIC)
May 28, 2014·Acta Oncologica·Michaela TonderPatrick Roth
Jul 27, 2014·Neuro-oncology·Martin J van den Bent, Walter Taal
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jul 2, 2015·Neuro-oncology·Kathryn M FieldMark A Rosenthal
Sep 1, 2015·Cell·Jedd D Wolchok
Oct 16, 2015·Expert Review of Neurotherapeutics·Omar Abdel-Rahman, Mona Fouad
Oct 31, 2015·Neuro-oncology·David A Reardon, Michael Weller
Mar 24, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric BouffetUri Tabori
Apr 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans VasenDetlef K Bartsch
May 14, 2017·Journal of Neuro-oncology·Marc C Chamberlain, Bryan T Kim
Nov 16, 2017·The New England Journal of Medicine·Wolfgang WickMartin J van den Bent

❮ Previous
Next ❯

Citations

Aug 1, 2020·Current Treatment Options in Oncology·Ashley P GhiaseddinDavid D Tran
Jan 29, 2019·Frontiers in Pharmacology·Ruo Qiao ChenXiao Qian Chen
Jan 1, 2018·JCO Precision Oncology·Elena FountzilasApostolia-Maria Tsimberidou
May 1, 2021·International Journal of Molecular Sciences·Sanjeev ChawlaHarish Poptani
Jun 12, 2021·Frontiers in Neuroscience·Luke MaggsSoldano Ferrone
Oct 12, 2021·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Danielle L WeilerJason R Powell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Scott GettingerMatthew D Hellmann
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Toshihiko DoiAtsushi Ohtsu
© 2022 Meta ULC. All rights reserved